# US 2013/0295185 A1 · Compounds and methods for inducing apoptosis in cancer cells using a bh3 alpha-helical mimetic

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0295185 A1
- Document ID: US20130295185A1
- Status: Published application
- Kind: A1
- Application number: 13/940,967
- Filed: 2013-07-12
- Published: 2013-11-07
- Earliest claimed: 2011-01-12
- Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc.; Intezyne Technologies, Inc.; Yale University
- Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc.; Intezyne Technologies, Inc.; Yale University
- Inventors: Said M. Sebti; Andrew D. Hamilton; Kevin Sill; Adam Carie
- Web page: https://patentgrep.com/patent/US20130295185A1

## CPC

- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 31/205: Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A61K 31/4035: Isoindoles, e.g. phthalimide
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/69: Boron compounds
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07C 59/70: Ethers of hydroxy-acetic acid {, e.g. substitutes on the ring}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

A novel BH3 α-helical mimetic, BH3-M6, which binds to Bcl-XL and prevents its binding to fluorescently-labeled Bak-BH3 peptide in vitro with an IC50 value of 734 nM is presented herein. BH3-M6 is a pan-Bcl-2 antagonist that inhibits the binding of Bcl-XL, Bcl-2 and Mcl-1 to multi-domain Bax or Bak, or BH3-only Bim or Bad in a cell-free system and in intact human cancer cells, freeing up pro-apoptotic proteins to induce apoptosis. BH3-M6-induced apoptosis is caspase- and Bax-dependent. Furthermore, human cancer cells with high Bcl-2 or Bcl-XL levels are more sensitive to BH3-M6-induced cell death, suggesting that this compound can overcome drug resistance due to Bcl-2 or Bcl-XL overexpression. The pan-Bcl-2 inhibitor BH3-M6 may be encapsulated in a micelle to provide a more bioavailable therapeutic agent. Specifically, the BH3-M6 compound may be encapsulated within a micelle comprising a multiblock copolymer according to the methods described herein.

## Claims

### Claim 1

A compound comprised of the following chemical structure:
or pharmaceutically acceptable salts, prodrugs, salts of a prodrugs and metabolites thereof.

### Claim 2

A micelle comprising a multiblock copolymer of formula I:
wherein:
R1 is —OCH3, —N3, or
n is 110 to 450;
m is 1 or 2;
x is 3 to 50;
y is 5 to 50; and
z is 5 to 50;
wherein the micelle encapsulates BH3-M6 or pharmaceutically acceptable salts, prodrugs, salts of a prodrugs and metabolites thereof.

### Claim 3 (depends on 2)

The micelle of claim 2, wherein R1 is —N3.

### Claim 4 (depends on 2)

The micelle of claim 2, wherein R1 is —CH3.

### Claim 5

A micelle comprising a crosslinked multiblock polymer of formula III:
III
wherein:
R1a and Rib are independently selected from —OCH3, —N3,
T is a targeting group moiety;
M is a metal ion;
n is 110 to 450;
w is 3 to 50;
x is 0 to 50, provided that the sum of w and x is no more than 50;
y is 5 to 50; and
z is 5 to 50;
wherein the micelle encapsulates BH3-M6 or pharmaceutically acceptable salts, prodrugs, salts of a prodrugs and metabolites thereof.

### Claim 6 (depends on 5)

The micelle of claim 5, wherein R1a and R1b are both —CH3.

### Claim 7 (depends on 5)

The micelle of claim 5, wherein M is iron.

### Claim 8

A method of treating cancer comprising administering a therapeutically effective amount of at least one pan-Bcl-2 inhibitor to a subject in need thereof wherein the at least one pan-Bcl-2 inhibitor is BH3-M6 or pharmaceutically acceptable salts, prodrugs, salts of a prodrugs and metabolites thereof.

### Claim 9 (depends on 8)

The method of claim 8, wherein the pan-Bcl-2 inhibitor is encapsulated in a multiblock copolymer of Formula I.

### Claim 10 (depends on 8)

The method of claim 8, wherein the pan-Bcl-2 inhibitor is encapsulated in a crosslinked multiblock polymer of Formula III.

### Claim 11 (depends on 8)

The method of claim 8, wherein the cancer is characterized by the overexpression of an anti-apoptotic Bcl-2 family protein.

### Claim 12 (depends on 8)

The method of claim 8, wherein the cancer is selected from the group consisting of breast cancer, non-small cell lung cancer, prostate cancer and adenocarcinoma.

### Claim 13 (depends on 8)

The method of claim 8, further comprising administering at least one active agent.

### Claim 14 (depends on 13)

The method of claim 13, wherein the active agent is a proteasome inhibitor.

### Claim 15 (depends on 14)

The method of claim 14, wherein the proteasome inhibitor is selected from the group consisting of CEP-1612, bortezomib, NPI-0052, PR-171 and MG-132.

### Claim 16

A method of inducing apoptosis in a cancer cell comprising administering at least one pan-Bcl-2 inhibitor to the cell wherein the at least one pan-Bcl-2 inhibitor is BH3-M6 or pharmaceutically acceptable salts, prodrugs, salts of a prodrugs and metabolites thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the pan-Bcl-2 inhibitor is encapsulated in a multiblock copolymer of Formula I.

### Claim 18 (depends on 16)

The method of claim 16, wherein the pan-Bcl-2 inhibitor is encapsulated in a crosslinked multiblock polymer of Formula III.

### Claim 19 (depends on 16)

The method of claim 16, further comprising administering at least one active agent.

### Claim 20 (depends on 19)

The method of claim 19, wherein the active agent is a proteasome inhibitor.

### Claim 21 (depends on 20)

The method of claim 20, wherein the proteasome inhibitor is selected from the group consisting of CEP-1612, bortezomib, NPI-0052, PR-171 and MG-132.

### Claim 22

A composition for treating cancer comprising:
at least one pan-Bcl-2 inhibitor wherein the at least one pan-Bcl-2 inhibitor is BH3-M6 or pharmaceutically acceptable salts, prodrugs, salts of a prodrugs and metabolites thereof; and
a pharmaceutically acceptable carrier.

### Claim 23 (depends on 22)

The method of claim 22, wherein the pharmaceutically acceptable carrier is a micelle multiblock copolymer of Formula I.

### Claim 24 (depends on 23)

The method of claim 23, wherein the at least one pan-Bcl-2 inhibitor is encapsulated in the micelle multiblock copolymer of Formula I.

### Claim 25 (depends on 22)

The method of claim 22, wherein the pharmaceutically acceptable carrier is a micelle crosslinked multiblock polymer of Formula III.

### Claim 26 (depends on 25)

The method of claim 25, wherein the at least one pan-Bcl-2 inhibitor is encapsulated in the micelle crosslinked multiblock polymer of Formula III.

### Claim 27 (depends on 22)

The method of claim 22, wherein the cancer is characterized by the overexpression of an anti-apoptotic Bcl-2 family protein.

### Claim 28 (depends on 22)

The method of claim 22, wherein the cancer is selected from the group consisting of breast cancer, non-small cell lung cancer, prostate cancer and adenocarcinoma.

### Claim 29 (depends on 22)

The method of claim 22, further comprising administering at least one active agent.

### Claim 30 (depends on 29)

The method of claim 29, wherein the active agent is a proteasome inhibitor.

### Claim 31 (depends on 30)

The method of claim 30, wherein the proteasome inhibitor is selected from the group consisting of CEP-1612, bortezomib, NPI-0052, PR-171 and MG-132.
